Bayer: Initiating a phase II trial of an investigational GIRK4 inhibitor in patients with atrial fibrillation.

Zhitongcaijing · 3d ago
Bayer: Initiating a phase II trial of an investigational GIRK4 inhibitor in patients with atrial fibrillation.